Aethlon to merge with North Immunology
Share
Aethlon Medical (NASDAQ:AEMD) and North Immunology entered a definitive all-stock merger agreement that will combine the companies around NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis and other immune-mediated diseases.
